MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Coherus Biosciences Inc

Chiusa

SettoreSettore sanitario

0.88 -2.22

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.87

Massimo

0.92

Metriche Chiave

By Trading Economics

Entrata

-5.9M

-57M

Vendite

-47M

7.6M

P/E

Media del settore

2.158

39.857

Margine di Profitto

-744.427

Dipendenti

221

EBITDA

115K

-44M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+347.78% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-8.1M

110M

Apertura precedente

3.1

Chiusura precedente

0.88

Notizie sul Sentiment di mercato

By Acuity

50%

50%

169 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Coherus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 lug 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 lug 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 lug 2025, 21:04 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 lug 2025, 23:43 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 lug 2025, 22:47 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:30 UTC

Discorsi di Mercato
Utili

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 lug 2025, 22:04 UTC

Discorsi di Mercato
Utili

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 lug 2025, 22:03 UTC

Acquisizioni, Fusioni, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 lug 2025, 21:58 UTC

Discorsi di Mercato
Utili

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 lug 2025, 21:57 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:47 UTC

Utili

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 lug 2025, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 lug 2025, 21:22 UTC

Acquisizioni, Fusioni, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 21:05 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:04 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 lug 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

17 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Coherus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

347.78% in crescita

Previsioni per 12 mesi

Media 4.03 USD  347.78%

Alto 7 USD

Basso 1.05 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

3

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.9209 / 1.05Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

169 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.